-
Mashup Score: 55
Following the approval of the first antibody-drug conjugates (ADCs) in the early 2000s, development has increased dramatically, with 14 ADCs now approved and >100 in clinical development. In lung cancer, trastuzumab deruxtecan (T-DXd) is approved in human epidermal growth factor receptor 2 (HER2)-mutated, unresectable or metastatic non-small cell lung cancer, with ADCs targeting HER3 (patritumab deruxtecan), trophoblast cell-surface antigen 2 (datopotamab deruxtecan and sacituzumab govitecan [SG]) and mesenchymal-epithelial transition factor (telisotuzumab vedotin) in late-stage clinical development.
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 54
Following the approval of the first antibody-drug conjugates (ADCs) in the early 2000s, development has increased dramatically, with 14 ADCs now approved and >100 in clinical development. In lung cancer, trastuzumab deruxtecan (T-DXd) is approved in human epidermal growth factor receptor 2 (HER2)-mutated, unresectable or metastatic non-small cell lung cancer, with ADCs targeting HER3 (patritumab deruxtecan), trophoblast cell-surface antigen 2 (datopotamab deruxtecan and sacituzumab govitecan [SG]) and mesenchymal-epithelial transition factor (telisotuzumab vedotin) in late-stage clinical development.
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet-
🚀 Just out in @Annals_Oncology: @etop_ibcsg's position statement on antibody-drug conjugates (ADC) in lung and breast cancer. Honored to be a part of it, diving into the current evidence & future directions for clinical ADC development https://t.co/vZfXEPkLQ5 https://t.co/qBI6QPGYjB
-
-
Mashup Score: 27Antonio Passaro on LinkedIn: #esmo #sboc - 1 month(s) ago
🌎 I am deeply honored to have been a part of the ESMO SUMMIT LATIN AMERICA in Sao Paolo del Brasile 🇧🇷 this past Saturday, discussing the evolving scenario…
Source: www.linkedin.comCategories: General Medicine News, Hem/OncsTweet-
@myESMO Summit Latin America was a success in São Paulo! 🇧🇷 Honoured to be there with many friends and colleagues!! @E_de_Azambuja @TeresaSAmaral @AndresC27622123 https://t.co/Z4uUKlAufe
-
-
Mashup Score: 14Bayer receives U.S. FDA Breakthrough Therapy designation for BAY 2927088 for non-small cell lung cancer harboring HER2 activating mutations - 2 month(s) ago
BAY 2927088 is an oral, small molecule tyrosine kinase inhibitor under development as a potential new targeted therapy for patients with NSCLC harboring HER2 activating mutations / Breakthrough Therapy designation is a process designed to expedite the development and review of investigational drugs that have potential to provide substantial impr…
Source: www.bayer.comCategories: General Medicine News, Hem/OncsTweet-
🔥@FDAOncology Breakthrough Therapy designation for the BAY-2927088 (oral non-covalent selective TKI) for #lungcancer harboring #HER2 activating mutations #LCSM https://t.co/ObtBB3IF5A
-
-
Mashup Score: 26Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients - PubMed - 3 month(s) ago
Epidermal growth factor receptor (EGFR) exon 20 insertions occur rarely among different cancer types, with the highest frequency reported among non-small-cell lung cancer (NSCLC) patients, particularly adenocarcinomas (ADCs). Exon 20 insertions fall back in the tyrosine kinase domain, and can be clu …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
RT @ABiomarkers: Hot of press, the last @ABiomarkers paper focused on #EGFR Exon 20 mutations in #NSCLC. https://t.co/xv8LaATw2J @OncoAler…
-
-
Mashup Score: 28Amivantamab-Based Regimens Show Anticancer Activity in EGFR-Mutated Advanced NSCLC - The ASCO Post - 5 month(s) ago
Widely anticipated findings from the MARIPOSA1 and MARIPOSA-22 trials were presented at the European Society for Medical Oncology (ESMO) Congress 2023, showing potentially improved outcomes with regimens incorporating the bispecific antibody amivantamab-vmjw for patients with advanced non–small cell lung cancer (NSCL) and epidermal growth factor receptor (EGFR) mutations. The studies were…
Source: ascopost.comCategories: General Medicine News, Oncologists2Tweet-
Thanks to @ASCOPost for spotlighting the remarkable outcomes unveiled at #ESMO23 regarding #amivantamab based regimens demonstrating potent anticancer activity in EGFR-mutated advanced NSCLC, in two different trials: MARIPOSA & MARIPOSA-2🦋 #LCSM @ASCO https://t.co/etkYfOafKS
-
-
Mashup Score: 1Takeda Provides Update on Lung Cancer Program - 7 month(s) ago
Takeda will be working with the FDA towards a voluntary withdrawal of EXKIVITY (mobocertinib) in the U.S. and globally where it is currently available.
Source: www.takeda.comCategories: Hem/Oncs, Latest HeadlinesTweet-
@TakedaOncology will be closing the #mobocertinib clinical trial program #LCSM 🔨 https://t.co/AU5Es19LpH
-
-
Mashup Score: 33
/PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the three-arm Phase 3 MARIPOSA-2 study…
Source: www.prnewswire.comCategories: Latest Headlines, Oncologists2Tweet-
🚨PressRelease by @JanssenGlobal The combo of amivantamab plus p-based chemo (w/ or w/out Lazertinib) vs chemo alone achieved a statistically significant & clinically meaningful improvement in PFS in NSCLC with EGFR mut’s after Osimertinib https://t.co/UyMy2PYdSa
-
-
Mashup Score: 0
Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the Conditional Marketing Authorisation Application (MAA) for KRAZATI ® ( adagrasib ) for treatment of patients with KRAS G12C -mutated advanced non-small cell lung cancer (NSCLC). Mirati disagrees with the opinion and intends to request a formal re-examination. CHMP states that KRAZATI has a positive risk-benefit profile, however, does not fulfill certain requirements for a Conditional Marketing Authorisation. Mirati believes KRAZATI addresses the Conditional Marketing Authorisation requirements despite there being a currently conditionally approved KRAS G12C inhibitor and that KRAZATI possesses a differentiated clinical profile. Key differentiators include KRAZATI’s efficacy profile, potential central nervous system activity and combinability with other agents,
Source: ir.mirati.comCategories: Hem/Oncs, Latest HeadlinesTweet-
PressRelease🚨 @EMA_News issued a negative opinion on the Marketing Authorization Application (MAA) for adagrasib @Mirati for treatment of patients with KRASG12C-mutated advanced NSCLC 🔨 @KRASKickers https://t.co/K3bi11rGcZ
-
-
Mashup Score: 3
/PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the Phase 3 PAPILLON study evaluating…
Source: www.prnewswire.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Exciting times ahead for #lungcancer treatment according to PressReleases #FLAURA2 ✅ #Tropion-Lung1 ✅❓(ILD G5…) #PAPILLON ✅ #WCLC23 #ESMO23 https://t.co/j3Ds2B1O5F
-
🚀 Just out in @Annals_Oncology: @etop_ibcsg's position statement on antibody-drug conjugates (ADC) in lung and breast cancer. Honored to be a part of it, diving into the current evidence & future directions for clinical ADC development https://t.co/vZfXEPkLQ5 https://t.co/qBI6QPGYjB